

radiotherapy of the chest wall as well as additional hormone therapy ( $n = 8$ ) and/or chemotherapy ( $n = 3$ ). Tumor distribution by stage was as follows: stage 0 (9.7%), stage I (22.6%), stage II (32.2%) and stage III (35.5%). Histopathologic study revealed invasive ductal carcinoma in 27 pts, 1 invasive lobular carcinoma and 3 ductal carcinoma in situ.

**Results:** The mean follow-up was 77.6 months (range, 7.3–231.8). Only one in-field local relapse was observed. Eight patients (25.8%) experienced metastatic tumor spread, in 7 patients (22.6%) a second malignancy was observed. Kaplan-Meier estimates of OS and DFS at 5 years were 77% (95%CI, 0.61–0.93) and 73% (CI, 0.57–0.91), respectively. Risk factors that reached statistical significance on DFS in the Cox regression model were stage of disease ( $p = 0.020$ ), lymph node involvement ( $p = 0.026$ ) and histopathological grading ( $p = 0.017$ ). None of the prognostic factors were found to be of statistical value for OS.

**Conclusion:** Stage of disease, lymph node involvement and histological differentiation are of prognostic impact on disease free survival.

310

PUBLICATION

### Male breast cancer – New prognostic factors?

N. Afonso, D. Pereira, C. Silva, C. Lopes. *Departments of Medical Oncology and Pathology, Portuguese Institute of Oncology, Porto, Portugal*

**Purpose:** Male breast cancer (MBC) is a rare disease and this explains our little knowledge in prognosis. Research around MBC is inspired in findings for this cancer in females. In a population of patients with histologically confirmed MBC, known in its clinical characteristics, we purposed to test the expression of the v6 isoform of CD44 protein and its impact in prognosis.

**Population and Methods:** For MBC patients treated in our institution we review the main clinical characteristics with a possible effect in prognosis and their survival patterns. In the biopsy tissue we checked the immuno-expression of CD44v6 protein. The statistical analysis focus was to find relations between classical clinical and pathological variables and the CD44v6 expression, in order to define the contribution of this new factor for survival in the context of MBC.

**Results:** We tested CD44v6 protein in 31 cases of MBC. In 19 (59%) it was positive. A significant difference between expression of CD44v6 and histological grade was found with a greater percent of expression in undifferentiated tumors ( $p = 0.03$ ). In tumors with positive estrogens receptors we found a greater expression of CD44v6 ( $p = 0.03$ ). The CD44v6 expression in 16 lymph nodes with tumor invasion was positive in 9, with some of discordance between expression of CD44v6 in the primary tumor and in lymph node metastases, in one case only the lymph node was positive for CD44v6, in 4 cases the lymph nodes metastases had a greater expression than the primary. There was no difference in survival between the two groups, with and without expression of CD44v6.

**Conclusions:** The expression of CD44v6 in our group of patients with MBC is similar to that found by other authors in female breast cancer. It seems that CD44v6 expression is present in more aggressive tumors and, although without statistical significance, associated with a worse survival and shorter disease free survival. Lymph node expression for CD44v6 is occasionally higher than in the primary tumor. Our results support the ongoing research for new prognostic factors in MBC, being necessary larger series of patients in order to identify independent prognostic factors.

with the "Talon" system for cranial sites or an acquaplast mask. Target volumes up to 500 cm<sup>3</sup> have been treated. Multiple lesions (up to 3) were treated in one set-up. The range of dose/fractionation schemes used was 15Gy/1f–70Gy/35f. Dose validation was carried out using film and TLD dosimetry.

**Results:** Optimal dose distributions were attainable using inverse treatment planning for IMRT delivery. These were found to encompass the target volumes accurately using dose validation phantom studies. Immobilisation methods used were accurate to within 2 mm as evidenced by weekly portal films.

**Conclusion:** IMRT using the Peacock system offers the advantages of delivery of conformal therapy to high doses safely and accurately. This provides the opportunity for dose escalation studies, re-treatment of previously treated tumours as well as treating multiple targets in one set-up. The system may be fitted to a conventional linac without major modifications.

312

ORAL

### Stereotactic radiotherapy in the treatment of ocular melanoma

S. Jaywant<sup>1</sup>, H. Michaels<sup>1</sup>, N. Laperriere<sup>2</sup>. <sup>1</sup>Princess Margaret Hospital, Clinical Physics, Toronto; <sup>2</sup>Princess Margaret Hospital, Radiation Oncology, Toronto, Canada

**Introduction:** Ocular melanoma is frequently treated by the interstitial implantation of 198Au seeds, by the application of 60Co plaques or 184Ta wire, by external beam radiotherapy using small 60Co beams or by proton therapy. The last technique, though very expensive, provides improved dose distributions and dose localizations in the treatment of tumours adjacent to critical normal tissues, thereby allowing dose prescriptions as high as 70 Gy in 5 fractions over 8–9 days.

**Purpose:** The technique of stereotactic radiotherapy on a linear accelerator is being used successfully in treating various sites in the brain such as craniopharyngioma, glioblastoma, meningioma, pituitary adenoma, etc. It combines stereotactic localization with fractionated dose delivery. It has now become possible to extend the technique to the treatment of ocular melanoma using the same fractionation scheme as in proton therapy but at a considerably lower cost.

**Methods:** Stereotactic radiotherapy treatments are delivered using the Radionics' couch mounted system on a Varian 2100C/D linear accelerator and 6 MV photons. The relocatable Gill-Thomas-Cosman (GTC) frame, with an eye fixation device developed here, is attached directly to the dental plate assembly. Treatment planning is accomplished by the new XKnife-4 software. Circular fields between 10 mm and 20 mm diameter with five arcs and a prescription of 70 Gy in 5 fractions over 10 days have been commonly used for treating five patients so far.

**Results:** The technique developed at the Princess Margaret Hospital for the treatment of ocular melanoma has yielded excellent localization and dose distributions.

313

ORAL

### Proton radiation therapy (PRT) for pediatric optic pathway gliomas: Comparison with 3D planned photon and a standard photon technique

M. Fuss<sup>1</sup>, E.B. Hug<sup>2,3</sup>, R.A. Schaefer<sup>2</sup>, M. Nevinny<sup>2</sup>, J.D. Slater<sup>2</sup>. <sup>1</sup>Depts. of Radiation Oncology, University of Heidelberg, Germany; <sup>2</sup>Radiation Medicine; <sup>3</sup>Pediatrics, Loma Linda University Medical Center, California, United States

**Purpose:** We compared PRT and its normal tissue (NT) sparing with two photon radiation treatment techniques for localized and extensive optic pathway tumors.

**Methods:** Based on CT data sets of 7 children, previously treated with PRT, we computed 3D photon and lateral photon plans using the same treatment planning software. Radiation exposure for NT and discrete organs at risk was quantified.

**Results:** Analysis for small (<20 cm<sup>3</sup>) and larger (>80 cm<sup>3</sup>) tumors showed that protons encompassed the smallest volumes of NT at all isodose levels. Comparable conformity and high dose gradient were achieved for protons and 3D photons in small tumors. However, differences became larger with increasing tumor volume and complexity. At low isodose levels 3D photons encompassed the highest amount of NT. PRT reduced doses to the contralateral optic nerve by 48% and 77% compared to 3D photons and lateral photons, respectively. Dose reductions with PRT were 11% and 16% for the chiasm, 13% and 16% for the pituitary gland, and 39% and 54% for the temporal lobes.

## Radiotherapy techniques

311

ORAL

### Tomotherapy with peacock: The University of California, Irvine experience

M. Al-Ghazi<sup>1</sup>, M. Ammirati<sup>2</sup>, J. Kuo<sup>1</sup>, Y. Qian<sup>3</sup>, N. Ramsinghani<sup>1</sup>, R. Yakoob<sup>1</sup>. <sup>1</sup>Departments of Radiation Oncology; <sup>2</sup>Neurosurgery, University of California, Irvine; <sup>3</sup>Kaiser Permanente, Los Angeles, CA, United States

**Purpose:** Intensity modulated radiotherapy (IMRT) offers unique advantages in radiation treatment planning and delivery. In this work, our experience using the NOMOS Peacock system for IMRT is summarised.

**Methods:** Dosimetric data were acquired to commission the system for clinical use. To date, 80 patients were treated using this system which is fitted to a Clinac 600C linac. Cranial as well as extracranial lesions have been treated using this modality. Immobilisation is achieved either